DiaSorin S.p.A., in partnership with QIAGEN, has announced the CE-marked launch of the LIAISON QuantiFERON-TB Gold Plus II assay. This next-generation, fully automated chemiluminescent immunoassay is designed for the detection of Mycobacterium tuberculosis infections. According to the announcement, the new assay delivers a 25% faster turnaround time and enables laboratories to test approximately 75% more patients per hour compared to the previous version. The assay is intended to optimize laboratory workflow and increase throughput in countries accepting the CE mark. No clinical study or trial results were mentioned or presented in the provided information.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaSorin S.p.A. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.